Are biotechs underestimating regulatory groundwork
Bio matters
Related Posts
myTomorrows and brainstrust partner to support patients living with brain cancer
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of […]
Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease
Four-year treatment slows cognitive decline with consistent safety profile Eisai has presented new clinical data […]
Genomics study launches to optimise childhood cancer care in Ireland
It is hoped that the MAGIC-I study will support earlier diagnosis and personalised treatment A […]